Vol 10, No 1 (January 2021): Translational Lung Cancer Research

Original Article

Preoperative systemic immune-inflammation index predicts survival and recurrence in patients with resected primary pulmonary sarcomatoid carcinoma
Qingpeng Zeng, Jiagen Li, Nan Sun, Qi Xue, Yushun Gao, Jun Zhao, Yousheng Mao, Juwei Mu, Dali Wang, Shugeng Gao, Jie He
Predictors of upstage and treatment strategies for stage IA lung cancers after sublobar resection for adenocarcinoma in situ and minimally invasive adenocarcinoma
Hang Su, Chang Gu, Yunlang She, Long Xu, Ping Yang, Huikang Xie, Shengnan Zhao, Chunyan Wu, Dong Xie, Chang Chen
Association between dietary sodium, potassium intake and lung cancer risk: evidence from the prostate, lung, colorectal and ovarian cancer screening trial and the Women’s Health Initiative
Dongfang You, Mingzhi Zhang, Wenjing He, Danhua Wang, Yang Yu, Zhaolei Yu, Theis Lange, Sheng Yang, Yongyue Wei, Hongxia Ma, Zhibin Hu, Hongbing Shen, Feng Chen, Yang Zhao
Circ-AASDH functions as the progression of early stage lung adenocarcinoma by targeting miR-140-3p to activate E2F7 expression
Yuanyong Wang, Yang Wo, Tong Lu, Xiao Sun, Ao Liu, Yanting Dong, Wenxing Du, Wenhao Su, Zhangfeng Huang, Wenjie Jiao
Outcomes for localized treatment of large cell neuroendocrine carcinoma of the lung in the United States
Michael S. May, Connor J. Kinslow, Christopher Adams, Anjali Saqi, Catherine A. Shu, Kunal R. Chaudhary, Tony J. C. Wang, Simon K. Cheng
A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients
Elisabetta Rossi, Michele Aieta, Alfredo Tartarone, Aldo Pezzuto, Antonella Facchinetti, Daniele Santini, Paola Ulivi, Vienna Ludovini, Luciana Possidente, Pasquale Fiduccia, Nadia Minicuci, Rita Zamarchi
Impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study
Céline Forster, Valérie Doucet, Jean Yannis Perentes, Etienne Abdelnour-Berchtold, Matthieu Zellweger, Mohamed Faouzi, Hasna Bouchaab, Solange Peters, Carlo Marcucci, Thorsten Krueger, Lorenzo Rosner, Michel Gonzalez
Genomic profiling of extracellular vesicle-derived DNA from bronchoalveolar lavage fluid of patients with lung adenocarcinoma
Seung Eun Lee, Ha Young Park, Jae Young Hur, Hee Joung Kim, In Ae Kim, Wan Seop Kim, Kye Young Lee
Prognostic significance of cribriform adenocarcinoma of the lung: validation analysis of 1,057 Japanese patients with resected lung adenocarcinoma and a review of the literature
Naoki Nakajima, Akihiko Yoshizawa, Mariyo Rokutan-Kurata, Misa Noguchi, Yuki Teramoto, Shinji Sumiyoshi, Kyoko Kondo, Makoto Sonobe, Masatsugu Hamaji, Toshi Menju, Hiroshi Date, Hironori Haga
Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer
Youli Luo, Yunpeng Yang, Peijian Peng, Jianhua Zhan, Zhihui Wang, Zhiquan Zhu, Zhonghan Zhang, Lin Liu, Wenfeng Fang, Li Zhang
Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer
Hengrui Liang, Chao Yang, Diego Gonzalez-Rivas, Yunpeng Zhong, Ping He, Hongsheng Deng, Jun Liu, Wenhua Liang, Jianxing He, Shuben Li
Toxicity after volumetric modulated arc therapy for lung cancer: a monocentric retrospective study
Vincent Bourbonne, Alice Delafoy, François Lucia, Gilles Quéré, Olivier Pradier, Ulrike Schick
A prognostic nomogram for lung adenocarcinoma based on immune-infiltrating Treg-related genes: from bench to bedside
Xiaofei Wang, Zengtuan Xiao, Jialin Gong, Zuo Liu, Mengzhe Zhang, Zhenfa Zhang
Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations
Ryo Ko, Takehito Shukuya, Chiyo K. Imamura, Takaaki Tokito, Naoko Shimada, Ryo Koyama, Kazuhiko Yamada, Hidenobu Ishii, Koichi Azuma, Kazuhisa Takahashi
Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective study
Yurie Seto, Yoshiko Kaneko, Takako Mouri, Hiroyuki Fujii, Satomi Tanaka, Shinsuke Shiotsu, Osamu Hiranuma, Yoshie Morimoto, Masahiro Iwasaku, Tadaaki Yamada, Junji Uchino, Koichi Takayama
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome
Alberto Pavan, Andrea Boscolo Bragadin, Lorenzo Calvetti, Alessandra Ferro, Elisabetta Zulato, Ilaria Attili, Giorgia Nardo, Alessandro Dal Maso, Stefano Frega, Andrea Giovanni Menin, Matteo Fassan, Fiorella Calabrese, Giulia Pasello, Valentina Guarneri, Giuseppe Aprile, PierFranco Conte, Rafael Rosell, Stefano Indraccolo, Laura Bonanno
Pretreatment neutrophil-to-lymphocyte ratio predicts treatment efficacy and prognosis of cytotoxic anticancer drugs, molecular targeted drugs, and immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Masashi Ishihara, Ryosuke Ochiai, Terunobu Haruyama, Takahiko Sakamoto, Shigeru Tanzawa, Takeshi Honda, Shuji Ota, Yasuko Ichikawa, Tsuyoshi Ishida, Kiyotaka Watanabe, Nobuhiko Seki
Can autoantibody tests enhance lung cancer screening?—an evaluation of EarlyCDT®-Lung in context of the German Lung Cancer Screening Intervention Trial (LUSI)
Sandra González Maldonado, Theron Johnson, Erna Motsch, Stefan Delorme, Rudolf Kaaks
A preclinical research platform to evaluate photosensitizers for transbronchial localization and phototherapy of lung cancer using an orthotopic mouse model
Tsukasa Ishiwata, Takeshi Seki, Alexander Gregor, Masato Aragaki, Yamato Motooka, Tomonari Kinoshita, Terunaga Inage, Nicholas Bernards, Hideki Ujiie, Zhenchian Chen, Andrew Effat, Juan Chen, Gang Zheng, Koichiro Tatsumi, Kazuhiro Yasufuku
A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401)
Masaaki Okajima, Satoru Miura, Satoshi Watanabe, Hiroshi Tanaka, Kazuhiko Ito, Takashi Ishida, Masato Makino, Akira Iwashima, Naoya Matsumoto, Kazuhiro Sato, Kosuke Ichikawa, Tetsuya Abe, Hirohisa Yoshizawa, Toshiaki Kikuchi
Synergy between early-incorporation immunotherapy and extracranial radiotherapy in metastatic non-small cell lung cancer
Parth A. Chodavadia, Corbin D. Jacobs, Frances Wang, Joseph K. Salama, Chris R. Kelsey, Jeffrey M. Clarke, Neal E. Ready, Jordan A. Torok
In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit
Yusuke Tomita, Bryan Oronsky, Nacer Abrouk, Pedro Cabrales, Tony R. Reid, Min-Jung Lee, Akira Yuno, Jonathan Baker, Sunmin Lee, Jane B. Trepel
Identifying optimal candidates for primary tumor resection among metastatic non-small cell lung cancer patients: a population-based predictive model
Hengrui Liang, Zhichao Liu, Jun Huang, Jun Liu, Wei Wang, Jianfu Li, Shan Xiong, Caichen Li, Bo Cheng, Yi Zhao, Fei Cui, Jianxing He, Wenhua Liang
Simultaneous analysis of ALK, RET, and ROS1 gene fusions by NanoString in Brazilian lung adenocarcinoma patients
Lázaro Antonio Campanha Novaes, Luciane Sussuchi da Silva, Pedro De Marchi, Rodrigo de Oliveira Cavagna, Flavia Escremim de Paula, Maicon Fernando Zanon, Adriane Feijó Evangelista, Eduardo Caetano Albino da Silva, Vinícius Duval da Silva, Letícia Ferro Leal, Rui Manuel Reis
High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC)
Florian Kocher, Arno Amann, Kai Zimmer, Simon Geisler, Dietmar Fuchs, Renate Pichler, Dominik Wolf, Katharina Kurz, Andreas Seeber, Andreas Pircher
Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)
Shinji Takeuchi, Noriko Yanagitani, Takashi Seto, Yoshihiro Hattori, Kadoaki Ohashi, Masahiro Morise, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto, Makoto Nishio, Shizuko Takahara, Takahiro Kawakami, Yasuhito Imai, Kenichi Yoshimura, Azusa Tanimoto, Akihiro Nishiyama, Toshinori Murayama, Seiji Yano
The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment
Shenglin Ma, Meiqi Shi, Xueqin Chen, Yong Wang, Zhenhua Yang, Analyn Lizaso, Min Li, Haiyan Li, Lu Zhang, Xinru Mao, Xingxiang Xu, Yong Song
cGAS-STING pathway expression as a prognostic tool in NSCLC
Kristine Raaby Gammelgaard, Birgitte Sandfeld-Paulsen, Stine Høvring Godsk, Christina Demuth, Peter Meldgaard, Boe Sandahl Sorensen, Martin Roelsgaard Jakobsen
Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab
Doran Ksienski, Elaine S. Wai, Deepu Alex, Nicole S. Croteau, Ashley T. Freeman, Angela Chan, Tiffany Patterson, Melissa Clarkson, Leathia Fiorino, Zia Poonja, David Fenton, Sarah Irons, Mary Lesperance
MRI radiomic signature predicts intracranial progression-free survival in patients with brain metastases of ALK-positive non-small cell lung cancer
Shijun Zhao, Donghui Hou, Xiaomin Zheng, Wei Song, Xiaoqing Liu, Sicong Wang, Lina Zhou, Xiuli Tao, Lv Lv, Qi Sun, Yujing Jin, Lieming Ding, Li Mao, Ning Wu
Development of a nomogram for predicting the operative mortality of patients who underwent pneumonectomy for lung cancer: a population-based analysis
Xiangyang Yu, Shugeng Gao, Qi Xue, Fengwei Tan, Yushun Gao, Yousheng Mao, Dali Wang, Jun Zhao, Yin Li, Feng Wang, Hong Cheng, Chenguang Zhao, Juwei Mu
Association between aspirin use and lung cancer incidence depends on high-frequency use, bodyweight, and age in U.S. adults
Xuesi Dong, Jieyu He, Lijuan Lin, Ying Zhu, Chao Chen, Li Su, Yang Zhao, Ruyang Zhang, Yongyue Wei, Feng Chen, David C. Christiani
Perioperative comparison of video-assisted thoracic surgery and open lobectomy for pT1-stage non-small cell lung cancer patients in China: a multi-center propensity score-matched analysis
Jinming Xu, Heng Ni, Yihe Wu, Jinlin Cao, Xingpeng Han, Lunxu Liu, Xiangning Fu, Yin Li, Xiaofei Li, Lin Xu, Yang Liu, Heng Zhao, Deruo Liu, Xin Peng, Jian Hu
Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience
Xinqing Lin, Haiyi Deng, Likun Chen, Di Wu, Xiaobo Chen, Yilin Yang, Tao Chen, Xiaohong Xie, Zhanhong Xie, Ming Liu, Ming Ouyang, Yinyin Qin, Shiyue Li, Nanshan Zhong, Jeffrey P. Gregg, Nobuyuki Horita, Yong Song, Chengzhi Zhou
A nomogram for predicting the risk of lymph node metastasis in T1–2 non-small-cell lung cancer based on PET/CT and clinical characteristics
Xiayi Lv, Zhigang Wu, Jinlin Cao, Yeji Hu, Kai Liu, Xiaona Dai, Xiaoshuai Yuan, Yiqing Wang, Kui Zhao, Wang Lv, Jian Hu

Review Articles on Multimodal Management of Locally Advanced N2 Non-small Cell Lung Cancer

Mediastinal staging for non-small cell lung cancer
Virginia Leiro-Fernández, Alberto Fernández-Villar
Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival
Ana Casal-Mouriño, Alberto Ruano-Ravina, María Lorenzo-González, Ángeles Rodríguez-Martínez, Alexandra Giraldo-Osorio, Leonor Varela-Lema, Tara Pereiro-Brea, Juan Miguel Barros-Dios, Luis Valdés-Cuadrado, Mónica Pérez-Ríos
Minimal invasive surgery in locally advanced N2 non-small cell lung cancer
Ana Karina Patané
Systematic review of stereotactic body radiotherapy in stage III non-small cell lung cancer
Olwen Leaman Alcibar, Ernest Nadal, Inmaculada Romero Palomar, Arturo Navarro-Martin
Induction treatment in patients with stage III non-small cell lung cancer
Ramón Palmero, Noelia Vilariño, Arturo Navarro-Martín, Ernest Nadal
Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer
Akira Hamada, Junichi Soh, Tetsuya Mitsudomi
Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer
Caroline Huynh, Logan A. Walsh, Jonathan D. Spicer
Prognostic factors in potentially resectable stage III non-small cell lung cancer receiving neoadjuvant treatment—a narrative review
Virginia Calvo, Carlos Aliaga, Carlos Carracedo, Mariano Provencio
Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer
Monika Pradhan, Mathieu Chocry, Don L. Gibbons, Boris Sepesi, Tina Cascone
Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer
Roxana Reyes, Noemi Reguart

Disclosure:

1. The series “Multimodal management of locally advanced N2 non-small cell lung cancer” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Mariano Provencio served as the unpaid Guest Editor for the series.